Description:
GSK1016790A is a novel and potent transient receptor potential vanilloid 4 (TRPV4) agonist. It has been used to demonstrate a role for TRPV4 in regulating urinary bladder activity and endothelial control of vascular tone. It elicited Ca2+ influx in mouse and human TRPV4 expressing HEK cells with EC50 values of 18 and 2.1 nM, respectively. It also evoked a dose-dependent activation of TRPV4 whole-cell currents at concentrations above 1 nM, which is 300 fold more potent than 4a-PDD. It was developed by GlaxoSmithKline.
- Molecular Weight:655.61
- Purity:>98 %
Molecular Formula:
C28H32Cl2N4O6S2
Canonical SMILES:
CC(C)CC(C(=O)N1CCN(CC1)C(=O)C(CO)NS(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)NC(=O)C3=CC4=CC=CC=C4S3
InChI:
InChI=1S/C28H32Cl2N4O6S2/c1-17(2)13-21(31-26(36)24-14-18-5-3-4-6-23(18)41-24)27(37)33-9-11-34(12-10-33)28(38)22(16-35)32-42(39,40)25-8-7-19(29)15-20(25)30/h3-8,14-15,17,21-22,32,35H,9-13,16H2,1-2H3,(H,31,36)/t21-,22-/m0/s1
InChIKey:
IVYQPSHHYIAUFO-VXKWHMMOSA-N
Solubility:
DMSO ≥ 33 mg/mL
Appearance:
White Solid
Application:
GSK1016790A regulats urinary bladder activity and endothelial control of vascular tone.
Storage: -20°C Freezer
Synonyms:
GSK1016790A; GSK-1016790A; GSK 1016790A. N-((S)-1-(4-((S)-2-(2,4-dichlorophenylsulfonaMido)-3-hydroxypropanoyl)piperazin-1-yl)-4-Methyl-1-oxopentan-2-yl)benzo[b]thiophene-2-carboxaMide; Weitere Informationen finden Sie
hier